December 2021
Vol 8 | Issue 558

Q&A with David Longo of Ordaos Bio

Chief Executive Officer

Principal Series:

Ordaōs founded with a revolutionary idea – drug discovery doesn’t have to rely on serendipity or be strangled by currently known science. We formed Ordaōs to custom design mini-proteins (50-200aa), previously only imagined, and accelerate the drug discovery and development process. Recent AI breakthroughs such as enhanced natural language algorithms, distributed cloud computational power and a generative learning engine enable Ordaōs to go beyond small molecule design to rapidly design, test, and optimize novel therapeutic proteins, all in silico, and maximize the speed and the probability of success in subsequent clinical development phases. Through these innovations, we deliver an early drug discovery cycle that takes minutes, not months.

Join us for a private Family Office Insights Webinar featuring David Longo, a Harvard-trained serial entrepreneur on a mission to reimagine drug design. David built Ordaos Bio to reduce the time-to-human of new drugs by at least two years using artificial intelligence. Ordaos has several programs in progress across HER2+ breast cancer, metastatic breast cancer, and AML/MDS and looks to disrupt the $250 billion protein therapeutics market.

December 15, 2021 at 2:15pm-3:15pm EST
RSVP & Confirmation Required


Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com


What does Ordaos do?

Our team created a powerful, AI-driven protein design engine that generates and optimizes therapeutic proteins against disease targets to save lives sooner. The system, Apollo, simultaneously optimizes for potency, immunogenicity, and specificity in silico. Ordaōs’ approach cuts a minimum of 2 years off the traditional process - adding revenue-generating patent life. We partner with innovative biotech and pharma companies to rapidly design small proteins. We chose this bigger challenge, mini-proteins, for its higher potential disease impact.

Who is Ordaos?

Our diverse team of 20 brilliant individuals includes 17 full time employees and 7 PhDs such as GSK veterans, quantum physicists, and AI scientists with deep protein backgrounds. And we’ve tested our team’s, and the system’s, efficacy through successful engagements with academic clients, such as Harvard and NYU Langone, as well as industry partners, such as the publicly traded Vyant Bio and private research group Cellaria, resulting in initial revenue and results sparking quotes like “You accomplished in four days what previously took us two years to accomplish.” In addition, we designed an advisory council of industry veterans across oncology, finance, regulatory, portfolio management, biostatistics, and AI to optimize our path to success.

What is the current opportunity to invest in Ordaos?

Ordaos is seeking $3MM in funding to expand our biotech partnerships, generate more in vitro proof, deliver on our R&D roadmap, and bolster our IP portfolio. These funds will help to secure two to three new partnerships in six months' time, increasing Ordaos' revenue run rate to $5MM by 2023.


David Longo of Ordaos Bio

Our diverse team of 20 brilliant individuals includes 17 full time employees and 7 PhDs such as GSK veterans, quantum physicists, and AI scientists with deep protein backgrounds. And we’ve tested our team’s, and the system’s, efficacy through successful engagements with academic clients, such as Harvard and NYU Langone, as well as industry partners, such as the publicly traded Vyant Bio and private research group Cellaria, resulting in initial revenue and results sparking quotes like “You accomplished in four days what previously took us two years to accomplish.” In addition, we designed an advisory council of industry veterans across oncology, finance, regulatory, portfolio management, biostatistics, and AI to optimize our path to success.
Contact David: dave@ordaos.bio